KIRKLAND, Wash., March 9 /PRNewswire/ -- ProteoTech Inc. announced today that both Dr. Alan D. Snow, Chairman, President & CSO, and Dr. Luke Esposito, Director of In Vitro Screening, will present at the 9th International Conference for Alzheimer's and Parkinson's Diseases, to be held in Prague, Czech Republic, March 11-15, 2009. On Sunday March 15, Dr. Alan D. Snow will give an oral presentation discussing promising results pertaining to ProteoTech's current Phase 1A human clinical trial with the small molecule Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. Dr. Snow's talk is entitled: "Exebryl-1: A Novel Small Molecule Currently in Human Clinical Trials as a Disease-Modifying Drug for the Treatment of Alzheimer's Disease."
Dr. Luke Esposito on Saturday March 14-Sunday March 15 will present during the "Synucleinopathies" poster session. Dr. Esposito's presentation is entitled: "Synuclere(TM): Development of a Novel Small Molecule that Effectively Reduces Alpha-Synuclein Aggregation and Improves Motor Dysfunction". Synuclere(TM) is a novel small molecule developed by ProteoTech that looks promising as a future disease-modifying treatment for Parkinson's disease and related disorders. ProteoTech's work in Parkinson's disease was partially funded by a LEAPS award from The Michael J. Fox Foundation for Parkinson's Research.
About ProteoTech: ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics targeting amyloid diseases. With over 175 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late-stage pre-clinical development with Synuclere(TM) for the treatment of Parkinson's disease, and Systebryl(TM) for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere(TM) as a nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes. For further information, please visit the Company's website at www.proteotech.com or contact us at firstname.lastname@example.org.
|SOURCE ProteoTech Inc.|
Copyright©2009 PR Newswire.
All rights reserved